BioNexus Gene Lab Corp
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $7.4M | $9.5M | $9.8M | $10.9M | $13.4M |
| Cost of revenue | $6.3M | $8.2M | $8.4M | $9.7M | $11.1M |
| Gross profit | $1.1M | $1.3M | $1.3M | $1.3M | $2.3M |
| Research and development | $50,670 | $47,511 | $54,982 | — | — |
| Operating expenses | $4.5M | $4.9M | $4.4M | — | — |
| Operating income | -$3.0M | -$1.6M | -$2.6M | -$291,177 | $1.1M |
| Interest expense | — | — | $13,929 | $12,479 | — |
| Pretax income | -$3.0M | -$1.6M | -$2.6M | -$303,656 | $1.0M |
| Income tax expense | $0 | -$3,494 | -$21,526 | -$52,310 | -$291,283 |
| Net income | -$3.0M | -$1.6M | -$2.6M | -$355,966 | $751,571 |
| Balance Sheet | |||||
| Cash and equivalents | $2.5M | $2.9M | — | — | $2.1M |
| Current assets | $5.4M | $7.4M | $8.0M | $6.0M | $7.1M |
| Total assets | $9.3M | $10.4M | $11.4M | $8.7M | $9.6M |
| Current liabilities | $520,957 | $2.0M | $1.6M | $2.0M | $2.3M |
| Total liabilities | $637,856 | $2.1M | $1.7M | $2.1M | $2.4M |
| Stockholders' equity | $8.6M | $8.3M | $9.7M | $6.7M | $7.2M |
| Cash Flow Statement | |||||
| Cash from operations | -$1.8M | -$2.1M | -$1.8M | $551,822 | $9,161 |
| Depreciation and amortization | $111,873 | $104,160 | $83,253 | $91,427 | $91,282 |
| Stock-based compensation | $794,770 | $141,000 | — | — | — |
| Capital expenditure | $36,971 | $226,989 | $149,398 | $0 | $3,162 |
| Free cash flow | -$1.9M | -$2.3M | -$2.0M | $551,822 | $5,999 |
| Impairments | $0 | $40,173 | — | — | — |
Shares outstanding 2.4M · Free float 48.3%
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.